98 Recruiting Trials

Clinical Trials
for Cancer in Idaho

98 clinical trials for Cancer are currently recruiting participants at study sites in Idaho. Study-related care is provided at no cost.

98
Recruiting trials
40
Study sites
11
Cities
23
Industry-sponsored
33
Phase 2
57
Phase 3

Cancer clinical trials in Idaho: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Idaho, recruiting cancer studies are concentrated in Boise, Coeur d'Alene, Post Falls and Nampa, with sites in 7 other cities. 23 of the 98 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 98 recruiting Cancer trials in Idaho

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
PHASE3 Jonesboro, Arkansas +4 sites NCT07391774
This trial is looking for women who are postmenopausal and have high stage breast cancer that is less likely to come back. Participants will compare hormone therapy and ribociclib to chemotherapy followed by hormone therapy and ribociclib.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
PHASE3 Fresno, California +4 sites NCT07195695
This trial is looking for adults who have had surgery for lung cancer and have specific genetic mutations. Participants will take either the new treatment zongertinib or standard care to see which is more effective at preventing cancer from returning.
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3 Birmingham, Alabama +4 sites NCT05633654
This trial is looking for adults with triple negative breast cancer that remains after surgery and treatment. Participants will receive an experimental treatment combining two medications after recovery from surgery.
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
PHASE3 Scottsdale, Arizona +4 sites NCT06467357
This trial is looking for adults with a type of cancer called advanced biliary tract cancer that expresses HER2. Participants will receive treatment to see how effective and safe it is compared to the standard treatment.
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
PHASE3 Mobile, Alabama +4 sites NCT07284849
This trial is looking for people with advanced colorectal cancer who have not received treatment for it yet. Participants will receive standard chemotherapy along with a medication called bevacizumab, with or without another drug called INCA33890.
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06793215
This trial is looking for adults with advanced lung cancer that has a specific mutation called KRAS G12C. Participants will be comparing two different treatment combinations to see which one works better.
Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3 Phoenix, Arizona +4 sites NCT06876714
This trial is looking for adults with HER2-positive breast cancer who have no residual invasive disease after chemotherapy. Participants will receive either 6 or 12 months of HER2-targeted medications to see which duration works best.
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
PHASE3 Tucson, Arizona +4 sites NCT06545955
This trial is looking for adults with a specific type of bladder cancer called carcinoma in situ (CIS) who have not responded to previous treatments. Participants will receive a treatment called nadofaragene firadenovec, either alone or with other therapies, to see how well it works.
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
PHASE3 Mobile, Alabama +4 sites NCT06561386
This trial is looking for people with advanced non-small cell lung cancer who have not received prior treatment. Participants will compare two different groups of treatment involving chemotherapy and specific medications.
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
PHASE3 Mobile, Alabama +4 sites NCT06627647
This trial is looking for adults with a specific type of lung cancer that has spread and has specific characteristics. Participants will receive one of two treatments combined with chemotherapy as part of their first treatment plan.
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
PHASE2 Anchorage, Alaska +4 sites NCT07063745
This trial is looking for people with advanced lung cancer who have a specific genetic change. Participants will receive either a combination of Navlimetostat, pembrolizumab, and chemotherapy or a placebo with the same treatments.
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
PHASE3 Tucson, Arizona +4 sites NCT06692738
This trial is looking for adults with a specific type of lung cancer that has spread or is hard to treat. Participants will receive a combination of a new drug and chemotherapy as their first treatment.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3 Birmingham, Alabama +4 sites NCT05812807
This trial is looking for people with early-stage triple-negative breast cancer who had no cancer left after previous treatments. Participants will either continue receiving pembrolizumab or just be monitored after surgery to see which approach works better to prevent cancer from coming back.
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
PHASE3 Anchorage, Alaska +4 sites NCT06592924
This trial is looking for men with prostate cancer that has spread and is responding poorly to current treatment. Participants will receive additional medication to see if it helps lower cancer growth and spread.
Recruiting
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
PHASE2 Birmingham, Alabama +4 sites NCT03851445
This trial is looking for patients with previously treated non-small cell lung cancer. Participants will undergo testing and may receive new therapies that target cancer growth compared to standard treatments.
Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3 Birmingham, Alabama +4 sites NCT04852887
This trial is looking for women with early-stage hormone-sensitive breast cancer who are interested in taking part in a study on surgery and hormone therapy without radiation. Participants will need to meet specific health criteria to join.
Recruiting

Where the Cancer studies are in Idaho

  • Kootenai Health - Coeur d'Alene, Coeur d'Alene62 trials
  • Kootenai Clinic Cancer Services - Post Falls, Post Falls61 trials
  • Kootenai Clinic Cancer Services - Sandpoint, Sandpoint54 trials
  • Saint Alphonsus Cancer Care Center-Nampa, Nampa50 trials
  • Saint Alphonsus Cancer Care Center-Caldwell, Caldwell46 trials
  • Saint Alphonsus Cancer Care Center-Boise, Boise45 trials

Counts are recruiting studies listing at least one site in Idaho, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Idaho: common questions

How many Cancer clinical trials are recruiting in Idaho?
TrialFinder currently lists 98 recruiting Cancer clinical trials with study sites in Idaho. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Idaho?
Study sites for the Cancer trials listed on this page include Boise. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Idaho?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Idaho also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Idaho?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Idaho.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →